Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Suzuken Co ( (JP:9987) ) has provided an announcement.
Suzuken has unveiled a three-year Medium-Term Management Plan running from the fiscal year ending March 2027 to March 2029, positioning it as a key execution phase toward achieving a sustainable 8% return on equity by the fiscal year ending March 2031. The plan responds to mounting pressure on traditional pharmaceutical distribution models from cost-containment policies and structural industry shifts, and aims to build a more resilient earnings base.
Under the slogan “Change makes Challenge, Challenge makes Change,” the group will transform its core pharmaceutical distribution operations into a next-generation model that monetizes service functions via fee-based businesses in addition to conventional margins. By enhancing order-to-delivery efficiency while maintaining stable supply, Suzuken seeks to diversify revenue sources and secure fair compensation for value-added services.
The company also plans to rebuild its business portfolio by deepening existing operations and forging alliances with external partners, combining its functions and assets to move into higher value-added healthcare models beyond traditional wholesaling. To support this shift, Suzuken will strengthen its management foundation through targeted talent development and recruitment in digital technologies and data analytics, as well as systematic training of next-generation leaders and broader group-wide collaboration.
The most recent analyst rating on (JP:9987) stock is a Buy with a Yen7100.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.
More about Suzuken Co
Suzuken Co., Ltd. is a Japan-based healthcare group primarily engaged in pharmaceutical distribution, supplying drugs as part of the country’s medical social infrastructure. Listed on the Prime Market of the Tokyo and Nagoya bourses and the Sapporo exchange, the company is shifting toward higher value-added services amid rising specialty drugs and logistics and personnel costs.
Average Trading Volume: 196,968
Technical Sentiment Signal: Buy
Current Market Cap: Yen301.6B
Find detailed analytics on 9987 stock on TipRanks’ Stock Analysis page.